Tags

Type your tag names separated by a space and hit enter

Prevention of Urinary Tract Infection with Oximacro, A Cranberry Extract with a High Content of A-Type Proanthocyanidins: A Pre-Clinical Double-Blind Controlled Study.
Urol J 2016; 13(2):2640-9UJ

Abstract

PURPOSE

Urinary tract infections (UTIs) are widespread and affect a large portion of the human population. Cranberry juices and extracts have been used for UTI prevention due to their content of bioactive proanthocyanidins (PACs), particularly of the A type (PAC-A). Controversial clinical results obtained with cranberry are often due to a lack of precise determination and authentication of the PAC-A content. This study used Oximacro (Biosfered S.r.l., Turin, Italy), a cranberry extract with a high content of PAC-A, to prevent UTIs in female and male volunteers.

MATERIALS AND METHODS

The Oximacro PACs content was assayed using the Brunswick Laboratories 4-dimethylaminocinnamaldehyde (BL-DMAC) method, and the dimer and trimer PACs-A and PACs-B percentages were determined via high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS/MS). A balanced group of female (ranging from 19 to over 51 years) and male volunteers (over 51 years) was divided into two groups. The experimental group received 1 capsule containing Oximacro (36 mg PACs-A) twice per day (morning and evening) for 7 days, and the placebo group was given the same number of capsules with no PACs.

RESULTS

Analysis of Oximacro revealed a high total PAC content (372.34 mg/g ± 2.3) and a high percentage of PAC-A dimers and trimers (86.72% ± 1.65). After 7 days of Oximacro administration, a significant difference was found between the placebo and Oximacro groups for both females (Mann-Whitney U-test = 875; P < .001; n = 60) and males (Mann-Whitney U-test = 24; P = .016; n = 10). When the female and male age ranges were analysed separately, the female age range 31-35 showed only slightly significant differences between the placebo and Oximacro groups (Mann-Whitney U-test = 20.5; P = .095; n = 10), whereas all other female age ranges showed highly significant differences between the placebo and Oximacro groups (Mann-Whitney U-test = 25; P = .008; n = 10). Furthermore, colony forming unit/mL counts from the urine cultures showed a significant difference (P < .001) between the experimental and the placebo groups (SD difference = 51688; df = 34, t = -10.27; Dunn-Sidak Adjusted P < .001, Bonferroni Adjusted P < .001).

CONCLUSION

Careful determination of the total PAC content using the BL-DMAC method and the authentication of PACs-A with mass spectrometry in cranberry extracts are necessary to prepare effective doses for UTI prevention. A dose of 112 mg Oximacro containing 36 mg PACs-A was found to be effective in preventing UTIs when used twice per day for 7 days.

Authors+Show Affiliations

Department of Life Sciences and Systems Biology, University of Turin, Via Quarello 15/A, Turin, Italy.Farmacia Antoniana, Viale Cesare Balbo, 3, 10040 San Gillio (TO), Italy.Department of Life Sciences and Systems Biology, University of Turin, Via Quarello 15/A, Turin, Italy.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27085566

Citation

Occhipinti, Andrea, et al. "Prevention of Urinary Tract Infection With Oximacro, a Cranberry Extract With a High Content of A-Type Proanthocyanidins: a Pre-Clinical Double-Blind Controlled Study." Urology Journal, vol. 13, no. 2, 2016, pp. 2640-9.
Occhipinti A, Germano A, Maffei ME. Prevention of Urinary Tract Infection with Oximacro, A Cranberry Extract with a High Content of A-Type Proanthocyanidins: A Pre-Clinical Double-Blind Controlled Study. Urol J. 2016;13(2):2640-9.
Occhipinti, A., Germano, A., & Maffei, M. E. (2016). Prevention of Urinary Tract Infection with Oximacro, A Cranberry Extract with a High Content of A-Type Proanthocyanidins: A Pre-Clinical Double-Blind Controlled Study. Urology Journal, 13(2), pp. 2640-9.
Occhipinti A, Germano A, Maffei ME. Prevention of Urinary Tract Infection With Oximacro, a Cranberry Extract With a High Content of A-Type Proanthocyanidins: a Pre-Clinical Double-Blind Controlled Study. Urol J. 2016 Apr 16;13(2):2640-9. PubMed PMID: 27085566.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevention of Urinary Tract Infection with Oximacro, A Cranberry Extract with a High Content of A-Type Proanthocyanidins: A Pre-Clinical Double-Blind Controlled Study. AU - Occhipinti,Andrea, AU - Germano,Antonio, AU - Maffei,Massimo E, Y1 - 2016/04/16/ PY - 2015/09/17/received PY - 2016/01/25/accepted PY - 2016/02/01/revised PY - 2016/4/18/entrez PY - 2016/4/18/pubmed PY - 2017/1/18/medline SP - 2640 EP - 9 JF - Urology journal JO - Urol J VL - 13 IS - 2 N2 - PURPOSE: Urinary tract infections (UTIs) are widespread and affect a large portion of the human population. Cranberry juices and extracts have been used for UTI prevention due to their content of bioactive proanthocyanidins (PACs), particularly of the A type (PAC-A). Controversial clinical results obtained with cranberry are often due to a lack of precise determination and authentication of the PAC-A content. This study used Oximacro (Biosfered S.r.l., Turin, Italy), a cranberry extract with a high content of PAC-A, to prevent UTIs in female and male volunteers. MATERIALS AND METHODS: The Oximacro PACs content was assayed using the Brunswick Laboratories 4-dimethylaminocinnamaldehyde (BL-DMAC) method, and the dimer and trimer PACs-A and PACs-B percentages were determined via high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS/MS). A balanced group of female (ranging from 19 to over 51 years) and male volunteers (over 51 years) was divided into two groups. The experimental group received 1 capsule containing Oximacro (36 mg PACs-A) twice per day (morning and evening) for 7 days, and the placebo group was given the same number of capsules with no PACs. RESULTS: Analysis of Oximacro revealed a high total PAC content (372.34 mg/g ± 2.3) and a high percentage of PAC-A dimers and trimers (86.72% ± 1.65). After 7 days of Oximacro administration, a significant difference was found between the placebo and Oximacro groups for both females (Mann-Whitney U-test = 875; P < .001; n = 60) and males (Mann-Whitney U-test = 24; P = .016; n = 10). When the female and male age ranges were analysed separately, the female age range 31-35 showed only slightly significant differences between the placebo and Oximacro groups (Mann-Whitney U-test = 20.5; P = .095; n = 10), whereas all other female age ranges showed highly significant differences between the placebo and Oximacro groups (Mann-Whitney U-test = 25; P = .008; n = 10). Furthermore, colony forming unit/mL counts from the urine cultures showed a significant difference (P < .001) between the experimental and the placebo groups (SD difference = 51688; df = 34, t = -10.27; Dunn-Sidak Adjusted P < .001, Bonferroni Adjusted P < .001). CONCLUSION: Careful determination of the total PAC content using the BL-DMAC method and the authentication of PACs-A with mass spectrometry in cranberry extracts are necessary to prepare effective doses for UTI prevention. A dose of 112 mg Oximacro containing 36 mg PACs-A was found to be effective in preventing UTIs when used twice per day for 7 days. SN - 1735-546X UR - https://www.unboundmedicine.com/medline/citation/27085566/Prevention_of_Urinary_Tract_Infection_with_Oximacro_A_Cranberry_Extract_with_a_High_Content_of_A_Type_Proanthocyanidins:_A_Pre_Clinical_Double_Blind_Controlled_Study_ L2 - http://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/3190/1054 DB - PRIME DP - Unbound Medicine ER -